- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Employers support right to sue
A national survey of employers, released jointly by the Menlo Park, CA-based Kaiser Family Foundation and the Washington-based Health Research and Educational Trust, found that smaller employers (three to 199 employees) are significantly more likely than larger employers (200 or more employees) to support a person's right to sue a health plan, and are somewhat more likely to support the right to appeal a health plan's decision to an independent reviewer. Two-thirds (67%) of smaller employers express support for the right to sue a health plan, compared with 28% of larger employers. Eighty-six percent of smaller employers and 74% of larger employers support independent review. However, the survey found that support for both the right to sue and independent review decreases if employers are told that the cost of health insurance might increase as a result.
A national survey of employers, released jointly by the Menlo Park, CA-based Kaiser Family Foundation and the Washington-based Health Research and Educational Trust, found that smaller employers (three to 199 employees) are significantly more likely than larger employers (200 or more employees) to support a person's right to sue a health plan, and are somewhat more likely to support the right to appeal a health plan's decision to an independent reviewer. Two-thirds (67%) of smaller employers express support for the right to sue a health plan, compared with 28% of larger employers. Eighty-six percent of smaller employers and 74% of larger employers support independent review. However, the survey found that support for both the right to sue and independent review decreases if employers are told that the cost of health insurance might increase as a result.
According to the survey, if the ability to have independent review might increase the cost of a family health insurance premium by $1 a month, smaller employer support drops to 72% and larger employer support drops to 60%. If the right to sue might increase the cost of a family health insurance premium by $5 per month, which is approximately the amount estimated by the Congressional Budget Office, smaller employer support drops from 67% to 50%. If the right to sue might add $30 per month to the cost of a family health insurance premium, which is substantially more than the CBO estimate, smaller employer support drops to 36%.
Very small business response
A separate national survey by the Kaiser Family Foundation of very small businesses only â those with three to 24 employees â found that 68% favor a federal law increasing patient protections, including the right to sue health plans, while 24% oppose such a law. Again, support drops when those surveyed are told that such a law would increase the cost of health insurance (48% favor, 40% oppose). If the cost of health insurance were to increase by $200 a year for a typical family policy, 52% of small businesses say they would likely pass some of the cost on to employees, while 36% would absorb the cost and 4% say they would drop coverage entirely. PR
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
To Tackle the Plastic Waste Crisis in Pharma, Here’s Where to Start
October 30th 2024By demonstrating big advancements in recycling, pharma companies will be much more likely to attract shareholders and other investors, giving themselves a leg up in the competition to lead the biopharmaceutical industry well into the future.
